JP2002507209A - カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物 - Google Patents

カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物

Info

Publication number
JP2002507209A
JP2002507209A JP50539899A JP50539899A JP2002507209A JP 2002507209 A JP2002507209 A JP 2002507209A JP 50539899 A JP50539899 A JP 50539899A JP 50539899 A JP50539899 A JP 50539899A JP 2002507209 A JP2002507209 A JP 2002507209A
Authority
JP
Japan
Prior art keywords
acid
hnf
hydroxy
dimethyl
coa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP50539899A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002507209A5 (https=
Inventor
バル−タナ，ヤコブ
Original Assignee
イスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヒーブルー・ユニバーシティ・オブ・エルサレム
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヒーブルー・ユニバーシティ・オブ・エルサレム filed Critical イスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヒーブルー・ユニバーシティ・オブ・エルサレム
Publication of JP2002507209A publication Critical patent/JP2002507209A/ja
Publication of JP2002507209A5 publication Critical patent/JP2002507209A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP50539899A 1997-06-26 1998-06-23 カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物 Ceased JP2002507209A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL12116597A IL121165A0 (en) 1997-06-26 1997-06-26 Pharmaceutical compositions containing carboxylic acids and derivatives thereof
IL121165 1997-06-26
PCT/IB1998/000968 WO1999000116A2 (en) 1997-06-26 1998-06-23 Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them

Publications (2)

Publication Number Publication Date
JP2002507209A true JP2002507209A (ja) 2002-03-05
JP2002507209A5 JP2002507209A5 (https=) 2005-12-22

Family

ID=11070308

Family Applications (1)

Application Number Title Priority Date Filing Date
JP50539899A Ceased JP2002507209A (ja) 1997-06-26 1998-06-23 カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物

Country Status (10)

Country Link
US (1) US6303653B1 (https=)
EP (1) EP1001755B1 (https=)
JP (1) JP2002507209A (https=)
CN (2) CN1261274A (https=)
AT (1) ATE508739T1 (https=)
AU (1) AU7783998A (https=)
CA (1) CA2294232A1 (https=)
IL (2) IL121165A0 (https=)
RU (1) RU2239427C2 (https=)
WO (1) WO1999000116A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519290A (ja) * 2007-02-26 2010-06-03 シンドロメクス リミテッド 心血管系障害の治療のための併用療法、組成物及び方法
JP2012515171A (ja) * 2009-01-14 2012-07-05 ヴァナス オンコロジー 組成物および使用の方法
JP2012522790A (ja) * 2009-03-31 2012-09-27 ウィッテン，マシュー，アール． 組成物および使用の方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020037876A1 (en) * 1998-06-25 2002-03-28 Yissum Research Development Company Of Hebrew University Of Jerusalem Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
US6410802B1 (en) 1999-04-01 2002-06-25 Esperion Therapeutics, Inc. Methods for synthesizing ether compounds and intermediates therefor
AU2000265105A1 (en) * 2000-08-02 2002-02-13 Pharmanutrients Methods and compositions for the prevention and treatment of syndrome x
JPWO2002024227A1 (ja) * 2000-09-20 2004-01-29 協和醗酵工業株式会社 腫瘍細胞増殖抑制剤
CA2425311C (en) 2000-10-11 2011-06-14 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN1894195A (zh) 2000-10-11 2007-01-10 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的醚化合物以及组合物
CN101426763A (zh) 2000-10-11 2009-05-06 埃斯佩里安医疗公司 用于胆固醇治疗和相关应用的硫化物和二硫化物化合物和组合物
JP2004531459A (ja) 2000-10-11 2004-10-14 エスペリオン セラピューティクス，インコーポレイテッド コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用
NO20006008L (no) * 2000-11-28 2002-05-29 Thia Medica As Fettsyreanaloger for behandling av inflammatoriske og autoimmune sykdommer
AU2003223930A1 (en) * 2002-06-14 2003-12-31 Novo Nordisk A/S Pharmaceutical use of boronic acids and esters thereof
ES2625429T3 (es) 2003-01-23 2017-07-19 Esperion Therapeutics Inc. Compuestos de hidroxilo y composiciones para el control del colesterol y utilizaciones correspondientes
JP2007525408A (ja) 2003-12-24 2007-09-06 エスペリオン セラピューティクス，インコーポレイテッド コレステロール管理および関連使用のためのケトン化合物および組成物
US20090018199A1 (en) * 2003-12-30 2009-01-15 Syndrome X Ltd. Methods of Administering 3, 3, 14, 14 Tetramethyl Hexadecane 1, 16 Dioic Acid
KR20050118057A (ko) * 2004-04-24 2005-12-15 김상희 아세틸디아실글리세롤류의 화합물을 유효성분으로함유하는 항암제 및 건강식품
US8410109B2 (en) 2005-07-29 2013-04-02 Resverlogix Corp. Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices
WO2007137864A1 (en) * 2006-06-01 2007-12-06 Eucro European Contract Research Gmbh & Co. Kg Use of inhibitors of pp2c for treating or preventing arteriosclerosis
US7777071B2 (en) 2006-08-11 2010-08-17 Ssv Therapeutics, Inc. Production of carnitine conjugate intermediates
PT2118074E (pt) 2007-02-01 2014-03-20 Resverlogix Corp Compostos para a prevenção e tratamento de doenças cardiovasculares
US8481084B2 (en) 2007-05-23 2013-07-09 Amcol International Corporation Cholesterol-interacting layered phyllosilicates and methods of reducing hypercholesteremia in a mammal
DE102007051339A1 (de) * 2007-10-26 2009-04-30 Müller-Enoch, Dieter, Prof. Dr. Verwendung von Verbindungen der Formel A-R-X oder deren pharmazeutisch akzeptablen Salze zur Herstellung einer pharmazeutischen Zubereitung zur Behandlung und zur Vorbeugung von Dyslipidämien
EP2085082A1 (en) * 2008-01-29 2009-08-05 Nutromnia S.R.L. Treatment of cognitive decline
SI2346837T1 (sl) 2008-06-26 2015-05-29 Resverlogix Corporation Postopki pripravljanja kinazolinonskih derivatov
US8952021B2 (en) 2009-01-08 2015-02-10 Resverlogix Corp. Compounds for the prevention and treatment of cardiovascular disease
KR101913109B1 (ko) 2009-03-18 2018-10-31 리스버로직스 코퍼레이션 신규한 소염제
US9757368B2 (en) 2009-04-22 2017-09-12 Resverlogix Corp. Anti-inflammatory agents
WO2011027257A2 (en) 2009-09-03 2011-03-10 Pfizer Vaccines Llc Pcsk9 vaccine
WO2012131504A1 (en) 2011-03-02 2012-10-04 Pfizer Inc. Pcsk9 vaccine
CA2851996C (en) 2011-11-01 2020-01-07 Resverlogix Corp. Pharmaceutical compositions for substituted quinazolinones
US10479752B2 (en) * 2011-12-08 2019-11-19 Syndromex Ltd. Deuterated tetramethyl dioic acids, compositions comprising them and uses thereof
US9073878B2 (en) 2012-11-21 2015-07-07 Zenith Epigenetics Corp. Cyclic amines as bromodomain inhibitors
US9765039B2 (en) 2012-11-21 2017-09-19 Zenith Epigenetics Ltd. Biaryl derivatives as bromodomain inhibitors
JP2016507496A (ja) 2012-12-21 2016-03-10 ゼニス・エピジェネティクス・コーポレイションＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｃｏｒｐ． ブロモドメイン阻害剤としての新規複素環式化合物
WO2015123291A1 (en) 2014-02-11 2015-08-20 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Pcsk9 vaccine and methods of using the same
US10111885B2 (en) 2015-03-13 2018-10-30 Resverlogix Corp. Compositions and therapeutic methods for the treatment of complement-associated diseases
EP3267989A4 (en) 2015-03-13 2018-11-07 Esperion Therapeutics, Inc. Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease
MA41793A (fr) 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
US20180092874A1 (en) * 2016-10-03 2018-04-05 Lincoln Memorial University Identification and use of very long chain dicarboxylic acids for disease diagnosis, chemoprevention, and treatment
US11555021B2 (en) * 2017-07-07 2023-01-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fatty acid derivatives and their use
MX2021015936A (es) 2019-06-21 2022-04-26 Esperion Therapeutics Inc Metodos para preparar acido bempedoico y composiciones del mismo.

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL64542A0 (en) 1981-12-15 1982-03-31 Yissum Res Dev Co Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them
DE3423166A1 (de) 1984-06-22 1986-01-02 Epis S.A., Zug Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten
GB8819110D0 (en) * 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
DE4224670A1 (de) 1992-07-25 1994-01-27 Boehringer Mannheim Gmbh Verwendung von â,w-Dicarbonsäuren als Fibrinogensenker
DK0661049T3 (da) * 1993-12-31 2000-02-14 Univ Limburg Anvendelse af essentielle fedtsyresammensætninger
IL119971A (en) 1997-01-07 2003-02-12 Yissum Res Dev Co Pharmaceutical compositions containing dicarboxylic acids and derivatives thereof and some novel dicarboxylic acids
EP1039892B1 (en) * 1997-02-21 2004-04-28 Abbott Laboratories Use of polyunsaturated fatty acids for reducing the incidence of necrotizing enterocolitis

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010519290A (ja) * 2007-02-26 2010-06-03 シンドロメクス リミテッド 心血管系障害の治療のための併用療法、組成物及び方法
JP2012515171A (ja) * 2009-01-14 2012-07-05 ヴァナス オンコロジー 組成物および使用の方法
JP2012522790A (ja) * 2009-03-31 2012-09-27 ウィッテン，マシュー，アール． 組成物および使用の方法

Also Published As

Publication number Publication date
US6303653B1 (en) 2001-10-16
WO1999000116A2 (en) 1999-01-07
IL133540A (en) 2009-09-22
IL121165A0 (en) 1997-11-20
EP1001755B1 (en) 2011-05-11
CA2294232A1 (en) 1999-01-07
CN1261274A (zh) 2000-07-26
WO1999000116A3 (en) 1999-08-12
AU7783998A (en) 1999-01-19
RU2239427C2 (ru) 2004-11-10
CN101129349A (zh) 2008-02-27
ATE508739T1 (de) 2011-05-15
EP1001755A2 (en) 2000-05-24

Similar Documents

Publication Publication Date Title
JP2002507209A (ja) カルボン酸類及びその誘導体並びにそれらを含有する医薬組成物
Urade et al. Prostaglandins and sleep–wake regulation
Baxter et al. Selective modulation of thyroid hormone receptor action
Bianco et al. Biochemistry, cellular and molecular biology, and physiological roles of the iodothyronine selenodeiodinases
Rogers et al. Translation of the Alzheimer amyloid precursor protein mRNA is up-regulated by interleukin-1 through 5′-untranslated region sequences
Chytil et al. Cellular vitamin A binding proteins
US6579900B2 (en) Anandamide amidase inhibitors as analgesic agents
US5981586A (en) Methods for treating proliferative and inflammatory skin diseases
JP2021107404A (ja) リソソーム蓄積症治療のための組成物及び方法
US7851507B2 (en) Use of hydroxyoleic acid and related compounds in the manufacture of drugs
US20100120742A1 (en) Rexinoid compound having alkoxy group
JP2020526505A (ja) 脂肪酸誘導体およびこれらの使用
JP2943089B2 (ja) イソプレノイドホスホリパーゼ▲ａ２▼阻害剤およびそれを包含する製剤
EP2745837B1 (en) Glomerulonephritis Treatment
CA2366281A1 (en) Novel ligands of nuclear receptors ppar's
EP1142870A1 (en) Novel ligands of nuclear receptor
US20020037876A1 (en) Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
JP2001521539A (ja) 炎症及び疼痛メディエーターのＮｆ−κＢ依存性生成阻害剤としてのイブプロフェンチオエステル（炎症及び疼痛メディエーターのＮｆ−κＢ依存性生成阻害剤としてのアリールプロピオン酸、アリール酢酸及びサリチル酸塩のＣｏＡチオエステル）
US20100331281A1 (en) Phospholipid compositions and uses thereof
JPWO2004093910A1 (ja) ＰＰＡＲδアゴニストによる脳神経変性疾患治療剤
US20180305305A1 (en) 2-beta-naphthyl-acetic acid analogs as akr1c3 inhibitors and methods of using same
Ford-Hutchinson Innovations in drug research: inhibitors of thromboxane and leukotrienes.
MXPA99012051A (en) Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them
WO2003004484A1 (en) Novel aliphatic compounds, synthesis method and method of using the same
Cheng et al. Leukotriene receptors in the airways

Legal Events

Date Code Title Description
A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20040824

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050616

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050616

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090210

A313 Final decision of rejection without a dissenting response from the applicant

Free format text: JAPANESE INTERMEDIATE CODE: A313

Effective date: 20090601

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20090707